产品
编 号：F746138
分子式：C9H11FN2O6
分子量：262.19
分子式：C9H11FN2O6
分子量：262.19
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1613589-24-4
产品详情
生物活性：
EIDD-2749 (4'-Fluorouridine) is an orally active RdRp inhibitor. EIDD-2749 effectively blocks the replication of RSV and SARS-CoV-2. EIDD-2749 also exhibits activity against HCV and lymphocytic choriomeningitis virus (LCMV). EIDD-2749 is a promising oral therapeutic candidate for COVID-19 and is also suitable for research on other RNA viruses.
体内研究：
EIDD-2749 (0.2, 1, 5 mg/kg; p.o.; single daily for 4 days) shows good orally efficacious in RSV infection mice model in a dose-dependent manner.EIDD-2749 shows high efficacious to SARS-CoV-2 infection and is effective with a single daily dose versus molnupiravir administered twice daily in vivo.Animal Model:Balb/cJ mice (RSV infection model).
Dosage:0.2, 1, 5 mg/kg
Administration:Oral administration; single daily for 4 days
Result:Resulted in a statistically significant reduction in lung virus load.
体外研究：
EIDD-2749 induces a delayed stalling of phosphodiester bond formation by RSV and SARS-CoV-2 RdRP.EIDD-2749 is rapidly anabolizes, metabolically stable, and potently antiviral in disease-relevant well-differentiated HAE cultures.EIDD-2749 shows a ≥17-fold increase in anti-RSV potency relative to that on HEp-2 cells; however, the low cytotoxicity levels remains unchanged (CC50 169 mM), resulting in a high SI (SI = EC50/CC50) of ≥1877.EIDD-2749 inhibits SARS-CoV-2 with an EC50 value of 0.2-0.6 M.EIDD-2749 has an EC50 of 1.86 μM in theVero E6 cell line, cytotoxicity with a CC50 of 380 μM, and stability in human plasma.
EIDD-2749 (4'-Fluorouridine) is an orally active RdRp inhibitor. EIDD-2749 effectively blocks the replication of RSV and SARS-CoV-2. EIDD-2749 also exhibits activity against HCV and lymphocytic choriomeningitis virus (LCMV). EIDD-2749 is a promising oral therapeutic candidate for COVID-19 and is also suitable for research on other RNA viruses.
体内研究：
EIDD-2749 (0.2, 1, 5 mg/kg; p.o.; single daily for 4 days) shows good orally efficacious in RSV infection mice model in a dose-dependent manner.EIDD-2749 shows high efficacious to SARS-CoV-2 infection and is effective with a single daily dose versus molnupiravir administered twice daily in vivo.Animal Model:Balb/cJ mice (RSV infection model).
Dosage:0.2, 1, 5 mg/kg
Administration:Oral administration; single daily for 4 days
Result:Resulted in a statistically significant reduction in lung virus load.
体外研究：
EIDD-2749 induces a delayed stalling of phosphodiester bond formation by RSV and SARS-CoV-2 RdRP.EIDD-2749 is rapidly anabolizes, metabolically stable, and potently antiviral in disease-relevant well-differentiated HAE cultures.EIDD-2749 shows a ≥17-fold increase in anti-RSV potency relative to that on HEp-2 cells; however, the low cytotoxicity levels remains unchanged (CC50 169 mM), resulting in a high SI (SI = EC50/CC50) of ≥1877.EIDD-2749 inhibits SARS-CoV-2 with an EC50 value of 0.2-0.6 M.EIDD-2749 has an EC50 of 1.86 μM in theVero E6 cell line, cytotoxicity with a CC50 of 380 μM, and stability in human plasma.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备